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Abstract
The 18 kDa translocator protein (TSPO) is an evolutionary conserved cholesterol binding
protein localized in the outer mitochondrial membrane. Expression of TSPO is upregulated
in activated microglia in various neuroinflammatory, neurodegenerative, and neoplastic dis-
orders. Therefore, TSPO radioligands are used as biomarkers in positron emission tomog-
raphy (PET) studies. In particular, a common A147T polymorphism in the TSPO gene
affects binding of several high affinity TSPO radioligands. Given the relevance of TSPO as
a diagnostic biomarker in disease processes, we systematically searched for mutations in
the human TSPO gene by a wide array of evolution and structure based bioinformatics tools
and identified potentially deleterious missense mutations. The two most frequently observed
missense mutations A147T and R162H were further analysed in structural models of
human wildtype and mutant TSPO proteins. The effects of missense mutations were studied
on the atomic level using molecular dynamics simulations. To analyse putative effects of
A147T and R162H variants on protein stability we established primary dermal fibroblast cul-
tures from wt and homozygous A147T and R162H donors. Stability of endogenous TSPO
protein, which is abundantly expressed in fibroblasts, was studied using cycloheximide pro-
tein degradation assay. Our data show that the A147T mutation significantly alters the flexi-
bility and stability of the mutant protein. Furthermore both A147T and R162H mutations
decreased the half-life of the mutant proteins by about 25 percent, which could in part
explain its effect on reduced pregnenolone production and susceptibility to neuropsychiatric
disorders. The present study is the first comprehensive bioinformatic analysis of genetic var-
iants in the TSPO gene, thereby extending the knowledge about the clinical relevance of
TSPO nsSNPs.
Introduction
The translocator protein 18 kDa (TSPO) is an 18 kDa evolutionary conserved cholesterol bind-
ing protein localized in the outer mitochondrial membrane (OMM) [1]. TSPO is widely
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expressed in many tissues with highest expression levels in steroid-synthesizing cells of endo-
crine organs [2, 3]. TSPO has been implicated in various cellular processes including steroid
hormone biosynthesis, oxidative stress, cell proliferation and apoptosis [4–6]; although recent
studies applying conditional and global knock out mice challenged to what extent TSPO is
essential for survival and steroid biosynthesis [7, 8].
TSPO expression which is low in healthy brain, is upregulated in neuroinflammation and
neurodegenerative disorders, such as Alzheimer disease, Parkinson disease, multiple sclerosis
and stroke [4, 9], but also during major depressive episodes [10]. Consequently, radioligands
that bind TSPO have been used in positron emission tomography (PET) studies [11] as a bio-
marker of neuroinflammation. In these studies, it has been shown that binding affinity of
TSPO PET radiotracers such as 11C-PBR28 is greatly affected by the non-synonymous rs6791
polymorphism [12], which is present in about 30% of the Caucasian population. The polymor-
phism was associated with predisposition to neuropsychiatric disorders such as panic disorder
[13], adult separation anxiety [14], bipolar disease [15], and fibromyalgia [16], as well as a
reduced pregnenolone production by peripheral blood cells [17].
Given the importance of TSPO as a biomarker for neuroinflammation and the potential
therapeutic implication of new TSPO ligands, we sought to systematically investigate genetic
variants in TSPO by several computational methods. Comparing the results of eight evolution
and structure based prediction tools used, we identified the most deleterious variants in the
TSPO gene. Interestingly, half of the identified deleterious missense mutations cluster in the
evolutionary highly conserved transmembrane domains 2 and 5, which are facing each other.
To study the impact of the two most frequently observed genetic variants, namely A147T and
R162H, at the structural level, models of the mutant proteins were built by homology model-
ling based on the Bacillus cereus TSPO crystal structure. Further, the native and mutant pro-
teins were analysed applying molecular dynamics experiments to determine whether the two
polymorphic sites could affect TSPO protein structure and stability. In addition, stability of wt
and mutant proteins was analysed in vitro in fibroblast cell lines carrying the respective geno-
types. This study is a first extensive in silico analysis of the TSPO gene serving as a resource for
future structure-function analyses of the TSPO protein.
Results
SNP dataset collection
The human TSPO gene reveals a total of 818 genetic variants in a data set from dbSNP and
60706 unrelated individuals from Exome Aggregation Consortium (ExAC) (Fig 1 and S1
Table). Of these, the majority is in the non-coding intervening regions of the gene (674 vari-
ants; 82.4%), and 52 (6.4%) genetic variants in the 5’- and 3’-untranslated regions of the
mRNA transcript. Genetic variants in the coding region include 52 (6.4%) non-synonymous
SNPs (nsSNPs) and 40 (4.8%) synonymous SNPs (sSNPs), which are evenly distributed across
the protein coding sequence. The nsSNPs were mapped to 43 residues (Fig 2), with 9 amino
acid residues harbouring two mutations each (G63S/D, A120P/G, R135C/H, P139T/S, A147T/
M, R156W/Q, R165W/Q, R166W/L, and E169Q/V). Since we sought to assess the effect of the
mutations on protein stability and structure, all synonymous and non-synonymous SNPs were
selected for subsequent analysis.
Identification of deleterious SNPs in TSPO gene
Computational methods such as Provean, SIFT, Polyphen2, PhD-SNP, SNAP2, SNPs&GO,
FATHMM and I-Mutant 3 were used to investigate the effect of mutations in the TSPO gene
on protein structure and stability (Table 1, S1 Table). Out of 52 nsSNPs analysed, 21 were
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predicted to be deleterious (Fig 2, Table 1) by consensus of all eight algorithms used. The
evolutionary conservation prediction tool ConSurf revealed that 11 out of 21 of the predicted del-
eterious mutations occur in highly conserved regions of the gene (S1 Fig, S2 Table). Interestingly,
9 out of these 11 mutations are located in two adjacent, evolutionary conserved amino acid
stretches in transmembrane domain 2 (TMD) (aa 44–65) and in TMD5 (aa 133–150) (S1 Fig),
suggesting their functional importance. Because all of the nsSNPs, except A147T, and R162H
have a very low global minor allele frequencies (MAF) in human populations (MAF<0.003), we
have selected these two SNPs (A147T and R162H) for further analysis. A147T SNP (MAF 0.30 in
European and 0.05 in Asian populations) affects binding of the second generation of the TSPO
ligands, and has been shown to be associated with anxiety disorder [14] and lowered production
of pregnenolone [17]. Functional consequences of the R162H SNP with a global MAF of 0.30
were not reported so far, so we also included this SNP in further analysis.
Analysis of sSNPs
Since it has been shown that the sSNPs could also affect protein translation efficiency and pro-
tein folding [19], we analysed codon usage of all 40 TSPO sSNPs using graphic codon usage
analyser accessible under http://gcua.schoedl.de/ [20]. Unexpectedly, 3 of the 40 sSNPs showed
significantly altered codon usage frequencies (S3 Table), expressed as relative adaptiveness
which consider the number of codons that code for the respective amino acid. Relative adap-
tiveness values for the SNPs at positions 113, 114, and 141 with CTG changed to CTA (both
Fig 1. Distribution of coding nsSNPs, coding sSNPs, intronic SNPs, and UTR SNPs in the human TSPO gene.
https://doi.org/10.1371/journal.pone.0195627.g001
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encode Leu) were reduced from 100 to 18. The sSNPs at positions 113 and 114 are of special
interest, as they reside in a rare codon usage cluster located between amino acids 100 and 121
(S2 Fig). Consequently, changes in the cluster of infrequently used codons could affect the tim-
ing of co-translational folding [21].
Homology modelling of human wt and mutant TSPO molecules
Regardless of remarkable progress in experimentally solving protein structures, the structure
of the human TSPO has not yet been determined. Only recently, the TSPO structures from
two bacterial species has been resolved at atomic resolution [22, 23], together with the struc-
ture of mouse TSPO, which has been determined by NMR [24]. These data can now be used
for homology modelling of native and mutant human TSPO proteins. The crystal structure of
Bacillus cereus TSPO with a protein sequence identity of 26.4% served as a template for the
homology modelling. The regions which could not be aligned to Bacillus cereus TSPO were
additionally modelled including the loops containing the sequences MAPPWV, FTEK, and
Fig 2. Identification of deleterious nsSNPs in human TSPO gene. Out of 52 nsSNPs analysed using a wide array of sequence and structure based computational
methods, 21 were predicted to be deleterious. Non-deleterious (blue), and deleterious (red), nsSNPs were plotted onto topology model of human TSPO which was
generated with PROTTER [18]. Cholesterol recognition/interaction amino acid consensus sequence (CRAC) domain is highlighted in black.
https://doi.org/10.1371/journal.pone.0195627.g002
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Table 1. List of nsSNPs in TSPO gene and their predicted Provean, SIFT, PolyPhen2, PhD-SNP, SNAP2, SNPs&GP, FATHMM, and iMutant3 scores. (N = non-del-
eterious, D = deleterious).
SNP ID Position Provean SIFT PolyPhen2 PhD-SNP SNAP2 SNPs&GO FATHMM iMutant3 Consensus 1–4 = N,
>5 = D
1 rs764229144 A2D Neutral Damaging possibly
damaging
Neutral Neutral Neutral Tolerated Neutral N
2 rs753849621 W5R Deleterious Damaging probably
damaging
Neutral Effect Neutral Tolerated Large decrease of
stability
D
3 rs765728030 A8T Neutral Tolerated probably
damaging
Neutral Neutral Neutral Tolerated Large decrease of
stability
N
4 rs567132675 G10S Deleterious Damaging probably
damaging
Neutral Effect Neutral Tolerated Large decrease of
stability
D
5 rs758845609 L13P Deleterious Damaging probably
damaging
Disease Effect Neutral Damaging Large decrease in
stability
D
6 rs187866832 A14V Neutral Tolerated benign Neutral Neutral Neutral Tolerated Neutral N
7 rs777431441 V21L Neutral Tolerated benign Neutral Neutral Neutral Tolerated Large decrease in
stability
N
8 rs748778969 G22A Deleterious Damaging benign Disease Effect Neutral Tolerated Large decrease in
stability
D
9 rs778946143 G28S Neutral Tolerated probably
damaging
Neutral Neutral Neutral Tolerated Large decrease in
stability
N
10 rs775263818 G30D Neutral Damaging probably
damaging
Disease Effect Neutral Tolerated Large decrease in
stability
D
11 rs566580110 R32C Neutral Tolerated probably
damaging
Disease Effect Neutral Damaging Large decrease in
stability
D
12 rs750994845 S41W Deleterious Tolerated benign Disease Neutral Disease Damaging Neutral N
13 rs550303992 P44L Deleterious Damaging probably
damaging
Disease Effect Disease Damaging Neutral D
14 rs566547284 G63S Neutral Tolerated probably
damaging
Disease Effect Neutral Tolerated Large decrease in
stability
D
15 rs139234976 G63D Deleterious Damaging probably
damaging
Neutral Effect Disease Tolerated Large decrease in
stability
D
16 rs756858058 Y65F Deleterious Damaging probably
damaging
Disease Effect Neutral Tolerated Large decrease in
stability
D
17 rs199899658 E70D Neutral Tolerated possibly
damaging
Neutral Neutral Neutral Tolerated Neutral N
18 rs749849080 T75I Deleterious Damaging possibly
damaging
Neutral Neutral Neutral Tolerated Neutral N
19 rs372235648 A78V Deleterious Damaging probably
damaging
Neutral Effect Neutral Tolerated Neutral N
20 rs746919529 G83R Deleterious Damaging probably
damaging
Disease Effect Disease Tolerated Neutral D
21 rs754824182 L84F Deleterious Tolerated probably
damaging
Disease Effect Neutral Damaging Large decrease in
stability
D
22 rs142445069 A94V Deleterious Damaging possibly
damaging
Disease Effect Neutral Tolerated Neutral N
23 rs775043588 P97L Deleterious Damaging probably
damaging
Disease Effect Neutral Tolerated Neutral D
24 rs760110771 A102T Neutral Tolerated benign Neutral Neutral Neutral Tolerated Neutral N
25 rs775654599 R103Q Neutral Damaging possibly
damaging
Neutral Effect Neutral Tolerated Large decrease of
stability
N
26 rs761543515 Q104E Neutral Tolerated benign Neutral Effect Neutral Tolerated Neutral N
27 rs143915407 G106V Deleterious Tolerated probably
damaging
Disease Effect Neutral Tolerated Neutral N
(Continued)
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HGWRGGRRLP. Subsequently, the data were subjected to a combined steepest descent and
simulated annealing minimization. The initial wt and the mutant A147T and R162H structures
were further refined and subjected to an energy minimization algorithm.
Table 1. (Continued)
SNP ID Position Provean SIFT PolyPhen2 PhD-SNP SNAP2 SNPs&GO FATHMM iMutant3 Consensus 1–4 = N,
>5 = D
28 rs752645452 V115I Neutral Damaging benign Neutral Neutral Neutral Tolerated Large decrease of
stability
N
29 rs148614502 A119V Neutral Tolerated probably
damaging
Neutral Neutral Neutral Tolerated Neutral N
30 rs200880548 A120P Deleterious Damaging possibly
damaging
Neutral Neutral Neutral Damaging Neutral N
31 rs779150979 A120G Deleterious Tolerated benign Disease Effect Disease Tolerated Large decrease of
stability
D
32 rs780467525 V124M Neutral Tolerated possibly
damaging
Neutral Neutral Neutral Tolerated Large decrease of
stability
N
33 rs373738253 P131L Deleterious Tolerated probably
damaging
Disease Effect Disease Tolerated Large decrease of
stability
D
34 rs773881998 A133T Deleterious Damaging probably
damaging
Disease Effect Disease Damaging Large decrease of
stability
D
35 rs767027529 A134T Neutral Tolerated possibly
damaging
Disease Neutral Neutral Tolerated Large decrease of
stability
N
36 rs775344095 R135C Neutral Tolerated benign Disease Neutral Neutral Tolerated Large decrease of
stability
N
37 rs760654235 R135H Neutral Tolerated probably
damaging
Neutral Neutral Neutral Tolerated Large decrease of
stability
N
38 rs757578697 P139T Deleterious Damaging probably
damaging
Disease Effect Disease Damaging Large decrease of
stability
D
39 n/a P139S Deleterious Damaging probably
damaging
Disease Effect Disease Damaging Large decrease of
stability
D
40 rs6971 A147T Deleterious Damaging benign Disease Effect Neutral Tolerated Large decrease of
stability
D
41 rs141002863 A147M Deleterious Damaging benign Disease Effect Neutral Tolerated Neutral N
42 rs774036527 L150F Deleterious Damaging probably
damaging
Disease Effect Disease Damaging Large decrease of
stability
D
43 rs771545866 V154I Neutral Tolerated benign Neutral Neutral Neutral Tolerated Large decrease of
stability
N
44 rs775001391 R156W Deleterious Damaging probably
damaging
Disease Effect Neutral Tolerated Neutral D
45 rs375211541 R156Q Neutral Tolerated benign Disease Effect Neutral Tolerated Large decrease of
stability
N
46 rs6972 R162H Neutral Tolerated benign Neutral Effect Neutral Tolerated Large decrease of
stability
N
47 rs776603192 R165W Neutral Damaging probably
damaging
Neutral Neutral Neutral Damaging Neutral N
48 rs761740678 R165Q Neutral Tolerated probably
damaging
Neutral Effect Neutral Tolerated Large decrease of
stability
N
49 rs765102690 R166W Neutral Damaging probably
damaging
Neutral Effect Neutral Damaging Neutral N
50 rs8192467 R166L Neutral Damaging benign Neutral Effect Neutral Tolerated Neutral N
51 rs9333342 E169Q Neutral Damaging possibly
damaging
Neutral Effect Neutral Tolerated Neutral N
52 rs568411305 E169V Neutral Damaging possibly
damaging
Neutral Effect Neutral Tolerated Neutral N
https://doi.org/10.1371/journal.pone.0195627.t001
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The refined models of native and mutant TSPO structures were superimposed to infer pos-
sible structural consequences of A147T and R162H mutations (Fig 3). The R162H substitution
resulted in local changes at the C terminus of TSPO molecule (Fig 3B), while the A147T muta-
tion (Fig 3A) caused considerable structural changes in TMD1, and the loop region 1 (LP1).
Molecular dynamics simulation of native and mutant TSPO proteins
To further understand the consequences of the missense mutations on TSPO structure and
stability, we conducted molecular dynamics simulation experiments using refined native and
mutant protein structures. We analysed the root mean square deviation (RMSD), root mean
square fluctuation (RMSF), and radius of gyration (Rg) between native and mutant molecules.
Two independent simulations were carried out for each wt and mutant structures, respectively,
and RMSD, RMSF, and Rg values were calculated from trajectory files. The overall protein
Fig 3. Spatial superposition of the native and mutant TSPO structures. Native human TSPO structure depicted in grey, was aligned with (A) A147T (red), and (B)
R162H (blue) TSPO mutant structures, respectively. Mutation at position A147T destabilized the whole protein, especially the loop LP1, which is involved in ligand
binding pocket and loop LP2. Mutation R162H, on the other hand, affected the conformation of the C-terminus only.
https://doi.org/10.1371/journal.pone.0195627.g003
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stability changes were assessed with the help of backbone RMSD values, which were calculated
for both native and mutant structures of the TSPO protein. Native and R162H structures
reached equilibrium states after 12 ns of simulation (3.27±0.29Å, and 3.41±0.43Å respectively)
(Fig 4A), whereas RMSD of the A147T mutant was significantly higher (5.14±0.63Å) during
the complete simulation period (Table 2). This increased structural deviation reflects the
impact of the amino acid substitution on protein stability. The A147T mutant results in a con-
formational change in protein structure which makes the backbone more flexible, and in turn
could affect ligand binding.
To evaluate the overall structural flexibility of native and mutant TSPO structures, RMSF
values were calculated from the simulation trajectory files, and were plotted per amino acid
residue (Fig 4B). The RMSFs of the A147T mutant structure (2.0±1.45Å) were notably higher
(Table 2) than that of wild-type, or R162H variant (1.43±0.7Å, and 1.51±1.17Å, respectively)
especially in the loop regions, thus suggesting greater structural flexibility of the mutant struc-
ture. Rg, which is the measure of compactness of protein structure and is defined as mass
weighted root mean square distance of atoms from their centre of mass, did not differ between
native and mutant structures (Table 2), suggestive of their similar overall protein dimensions.
In conclusion, our MDS results suggest that both A147T and R162H mutations cause a sig-
nificant structural change, resulting in higher overall flexibility when compared to the native
protein, which could affect binding affinity of TSPO ligands.
Analysis of protein stability
Next, we aimed to analyse the stability of native and mutant proteins in living cells using the
cycloheximide (CHX) chase protein degradation assay. We chose primary dermal fibroblasts
which were genotyped prior to assay performance. Primary dermal fibroblasts express robust
amounts of TSPO which localises to mitochondria (Fig 5A), as verified by co-localisation with
ATP synthase beta subunit (ATPB). A rabbit polyclonal affinity purified antibody, TSPO-MIL,
which recognized an epitope comprising the last 14 amino acids of human TSPO, revealed a
single 18 kDa band (Fig 5B) in western blots from fibroblast protein extracts. The specificity of
the TSPO-MIL antibody was confirmed with peptide blocking experiments (S3 Fig). For the
cycloheximide chase assay, we generated six primary dermal fibroblast cell lines from two
healthy donors each carrying either wild-type or a homozygous genotype for the A147T or
R162H TSPO variants. The TSPO protein stability was assessed by incubating cells for a maxi-
mum of 24 hours with 25 μg/ml of CHX, a well-known inhibitor of eukaryotic translation. The
TSPO protein expression was quantified at different time points after CHX treatment as per-
centage of the initial TSPO protein level (0h of CHX treatment) (Fig 5C), and normalised to
beta 1 tubulin (BTUB1) expression. Wild-type TSPO remained stable even after 24 hours (107
±5%), whereas both mutant proteins showed significant protein degradation. The A147T
mutant showed a tendency of degradation after 16 hours (93±9%), and the protein amount
was further reduced to 75±5% of initial values after 24h, whereas R162H mutant protein levels
were likewise reduced to 76±13% only at the final time point (Fig 5D). Results from protein
degradation analysis suggest that higher structural flexibility of both mutant proteins is accom-
panied by decreased protein stability.
Discussion
In this study, we conducted systematic bioinformatic analysis of the human TSPO gene with
the aim to identify potential deleterious nsSNPs and their effect on protein structure and sta-
bility. SNPs are common genetic variants that occur at a frequency of approximately 1 in 300
bp throughout the human genome [25]. With the number of newly identified SNPs rapidly
Analysis of TSPO genetic variants
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growing, reaching over 135 million validated SNPs in NCBI dbSNP database (build 150), there
is a need to prioritize SNPs that are functionally deleterious from neutral SNPs [26]. The
nsSNPs represent a small proportion of all SNPs which lead to amino acid change that could
cause a loss of thermodynamic stability, as well as aberrant folding of mutated protein.
Changes in amino acid properties could disrupt local environment by changing protein´s size,
hydrophobic contacts, surface charge distribution and residue-solvent interactions [27], how-
ever if they occur at regions which are non-essential for the protein function they will be prob-
ably neutral. Therefore, numerous bioinformatics tools have been developed to predict the
impact of amino acids substitution on protein structure and function. It is assumed that delete-
rious mutations are most likely to occur in evolutionary conserved regions [28], thus allowing
us to identify amino acid residues that could be functionally important. In fact, amino acid res-
idues which evolve under strong purifying selection are found to be most likely associated with
human diseases [29]. We indeed identified two deleterious mutation clusters in the highly con-
served regions in TMDs 2 and 5. These two adjacent transmembrane domains encompass a
cholesterol recognition/interaction amino acid consensus sequence (CRAC) domain, which is
essential for binding of cholesterol and other TSPO ligands. However, covariance analysis of
over 2000 TSPO sequences [30] have identified robust association between helices 4 and 5,
which is suggestive of their critical role for the stability and function of TSPO. Consequently,
we expect that mutations in highly conserved regions in TMDs 2, 4, and 5 will have severe con-
sequences on TSPO ligand binding and function.
From the all nsSNPs analysed, only A147T and R162H variants were present in human
populations with a frequency of about 30%, whereas all the other nsSNPs were very rare
(MAF<0.003). The effect of A147T mutation on pregnenolone synthesis, and on the protein
structure has been demonstrated in previous studies [17, 22, 31, 32], however only one study
so far investigated role of R162H mutation in mood disorder [33]. Nevertheless our computa-
tional analysis has shown that about 40 percent of all variants could have deleterious effect on
protein structure and function. The high number of identified deleterious mutations could be
explained by the evolutionary conservation of TSPO protein.
Since it has been shown that codon usage could compromise protein structure and function
[19, 21, 34], we additionally analysed codon usage in the TSPO gene. We identified three poly-
morphisms located in a rare codon cluster between amino acids 110 and 124, which could
affect timing of folding and insertion of TSPO into the membrane. As previously shown [21],
exchange of the frequent codons with rare codons in the cluster of infrequently used codons
Fig 4. Backbone RMSD and per-residue RMSF values of native and mutant structures of the TSPO protein. (A)
The RMSD values of native and mutant structures are shown as a function of time. (B) Central alpha carbon RMSF per
residue of native, and mutant systems are shown. Transmembrane domains are depicted with grey cylinders. Blue, red
and green lines indicate native, A147T and R162H mutations, respectively.
https://doi.org/10.1371/journal.pone.0195627.g004
Table 2. Average structural properties calculated for full length wt, A147T, and R162H TSPO models and corre-
sponding standard deviations (in parentheses).
TSPO wt A147T R162H
Backbone RMSD (Å) 3.27 (0.29) 5.14 (0.63) 3.41 (0.43)
Cα-RMSD (Å) 3.24 (0.30) 5.03 (0.61) 3.36 (0.43)
Cα-RMSF (Å) 1.43 (0.70) 2.00 (1.45) 1.51 (1.17)
Rg-protein (Å) 18.18 18.08 18.58
 Significant at p<0.05.
https://doi.org/10.1371/journal.pone.0195627.t002
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could influence the translation rate, which in turn may potentially affect protein folding. Nev-
ertheless, possible effects of TSPO sSNPs on protein folding need to be validated experimen-
tally. Micro Scale Thermophoresis (MST) which is very sensitive to changes in protein
structure and conformation or trypsin accessibility assay may possibly be performed, however
for this type of experiments, proteins needs to be heterologously expressed.
While the physiological role of TSPO is still under investigation, it is used routinely as a bio-
marker for various neurodegenerative, neuroinflammatory and psychiatric disorders [35–37],
although the binding of high affinity PET ligands has been shown to be dependent on the
TSPO genotype, specifically the A147T variant [38]. Previous studies [22, 31] have demon-
strated the structural impact of the A147T mutation in bacterial and in mouse system, however
a number of discrepancies have been observed between structures of prokaryotic and mamma-
lian TSPO homologues. TSPO from Rhodobacter sphaeroides has dimeric organisation, and
substitution of A139T, which is equivalent to the human A147T mutation, resulted in confor-
mational changes in LP1, CRAC domain, and TMD2. On the other side, the NMR structure of
a A147T mouse TSPO showed contradictory results. The mouse TSPO has been shown to
exist as a monomer, with the A147T mutation having only an effect on TMD1 and LP1, with-
out alterations in CRAC domain. Furthermore recent data showed that mouse TSPO exist in
dynamic monomer-dimer equilibrium in the membrane [39].
To study the impact of mutations at the structural level, we generated high quality structures
of human native and mutant TSPO proteins by homology modelling using the Bacillus cereus
structure as most suitable template. Even though we used the bacterial TSPO structure as a tem-
plate for homology modelling, our results concerning the A147T mutation are more similar to
the mouse model of A147T polymorph [31] then to the bacterial A139T [22], which has addi-
tional 7.70o tilt of TMD2 towards TMD5, an orientation which could not be observed in our
model. In a next step, we analyzed the impact of A147T and R162H mutations on the protein
structure. Our MDS experiments were conducted over a period of 30 ns and showed that the
A147T mutant presented higher flexibility in the loop regions when compared to the native pro-
tein. We suggest that, this increased structural flexibility possibly affects ligand binding. Our
data indicate that the TSPO protein is highly dynamic in the absence of a ligand, which is
reflected by high RMSD values, as expected for the naturally flexible protein like TSPO.
To test whether higher flexibility of the mutant protein could affect its stability, we esti-
mated half-life kinetics of native and mutant proteins in human dermal fibroblasts, which
were generated from two healthy donors each carrying a specific genotype. TSPO as a integral
membrane protein has a relatively long half-life of 54.4±12 hours [40]. Nevertheless, using
CHX as a potent translational inhibitor, we could show that both mutants have significantly
shorter half-life kinetics suggestive of altered protein stability. It is of note that from the fairly
long half-life of TSPO protein, we did not expect to see great differences in half-life kinetics
between native and mutant proteins due to the limitations of CHX degradation assay which
can be performed for a maximum of 24 hours. We can only speculate that a shortened half-life
of the mutant A147T protein could explain its association with predisposition to various disor-
ders [13–16] and reduced pregnenolone synthesis [17].
Fig 5. Analysis of protein stability by the cycloheximide protein degradation assay of wt and mutant TSPO proteins. (A) TSPO is
localized to mitochondria in primary dermal fibroblasts. (B) Lysates of human primary fibroblast cells were subjected to Western blotting
to detect endogenous TSPO. (C) Fibroblasts from carriers of wt and homozygous A147T and R162H mutations of TSPO were treated with
cycloheximide (25 μg/ml) for the indicated times, and endogenous TSPO was then detected by specific rabbit anti-TSPO antibody. Equal
amounts of protein were subjected to Western blot analyses, as determined by comparing the amount of beta 1 tubulin. (D) Densitometry
results for endogenous TSPO after treatment with cycloheximide were quantified as percentage of the initial TSPO protein level (0h of CHX
treatment) and normalized to the intensity of beta 1 tubulin, and then plotted. Data are shown as mean ± SEM from three independent
experiments.
https://doi.org/10.1371/journal.pone.0195627.g005
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In summary, using a combined bioinformatics approach we identified several potentially
deleterious SNPs which could affect the structure and stability of the TSPO protein. The struc-
tural consequences of A147T and R162H nsSNPs as predicted using MDS have shown a signif-
icantly higher flexibility of mutant structures, which was associated with a shortened half-life
of mutant proteins. Our study provides further insights into the structural consequences of
A147T mutation and the first characterisation of R162H variant for the human TSPO protein
and may facilitate the virtual screening for novel TSPO ligands. Nevertheless, the three-dimen-
sional crystal structures of the human TSPO proteins are still necessary for validation of struc-
tural changes suggested by our approach.
Material and methods
Dataset collection
SNPs of the human TSPO gene were retrieved from the National Center for Biotechnology
Information (NCBI) SNPs database, (dbSNP, build 141) [41] and Exome Aggregation Consor-
tium (ExAC) database, [42]. All redundant, outdated and SNPs in non-canonical transcripts
were removed. The amino acid sequence of human TSPO (accession number: AAQ75703.1)
was retrieved from the NCBI website.
Computational methods for detection of deleterious mutations
For prediction of the effect of nsSNPs on the protein structure and stability we used eight
computational algorithms. Protein Variation Effect Analyzer, (PROVEAN) [43], predicts the
functional impact of protein sequence variations as "neutral" or "deleterious". The sorting
intolerant from tolerant (SIFT) method [44], which is based on the degree of conservation of
amino acids in sequence alignments, predicts whether an amino acid substitution affects pro-
tein function. SIFT assigns scores where a variant with a score less than 0.05 is considered dele-
terious, whereas a variant with a score greater than 0.05 is considered tolerated. Polymorphism
Phenotyping v2 (PolyPhen-2) [45] is a tool which predicts possible impact of an amino acid
substitution on the structure and function of a human protein using straightforward physical
and comparative considerations. Mutations with probabilistic score bellow 0.15 are classified
as benign, the ones in the range of 0.15 to 0.84 are classified as "possibly damaging", and muta-
tion is classified as "most likely damaging" if the score is higher than 0.85. Predictor of human
Deleterious Single Nucleotide Polymorphisms (PhD-SNP) [46] is a Support Vector Machine
(SVM) single sequence based method which predicts whether a nSNP is a neutral polymor-
phism or a disease associated polymorphism. Screening for Non-Acceptable Polymorphisms 2
(SNAP2) [47] method utilizes sequence information, secondary structure and residue conser-
vation as well as neural networks to predict whether the mutation is neutral or non-neutral.
SNPs&GO [48] is SVM based method which predicts if a given single point protein variation
can be classified as disease associated or neutral using evolutionary information, and functions
encoded in gene ontology terms. Mutations with a score greater than 0.5 are classified as dis-
ease related. Functional Analysis through Hidden Markov Models (FATHMM) [49] predicts
the functional effects of protein missense mutations as tolerated or damaging, by combining
sequence conservation within hidden Markov models (HMMs). I-Mutant 3 [50] calculates the
thermodynamic stability change between wild type and mutant proteins. A single amino acid
substitution can result in a significant change in protein stability, which is denoted by the pro-
tein stability free energy change (DDG) value. I-Mutant 3 predictions are classified into three
classes: destabilizing mutations (DDG<-0.5 Kcal/mol), stabilizing mutations (DDG>0.5 Kcal/
mol) and neutral mutations (-0.5< = DDG< = 0.5 Kcal/mol). We additionally estimated the
evolutionary conservation rate of each residue in TSPO using ConSurf [51], which quantifies
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the degree of conservation for each amino acid position in a given alignment. The extent of
conservation of each residue is presented as a score in the range of 1–9, with 1 denotes highly
variable sites, and 9 evolutionary conserved sites.
Effect of synonymous mutations on protein structure and function were probed using
codon usage analyser [20]. The codon quality of coding sequences can be represented as
codon usage frequency or as relative adaptiveness values. In contrast to the codon usage fre-
quency the relative adaptiveness takes into account the number of codons which code for the
respective amino acid, and is obtained by setting the codon with the highest frequency value to
100%, and all other codons for the same codon are scaled accordingly.
Homology modeling of the human TSPO structures
Homology model of human TSPO was built using YASARA molecular modelling program ver-
sion 16.4.6 [52]. The hm_build.mcr macro of the YASARA software was used with the default
parameters except the maximum oligomerization state was set to one. The amino acid sequence
of TSPO (accession number: AAQ75703.1) was submitted to modeling, and template structures
were searched by running six iterations of PSI-BLAST. For the top scoring templates (PDB ID:
4UC1, 4RYO, and 4UC3) from the protein data bank a total of 6 models were created, and the
quality of the model structure was evaluated by considering the overall Z-score. The Z-score has
been defined as the weighted averages of the individual Z-scores using the formula, Z-score =
0.1456 x Dihedrals + 0.3906 x Packing1D + 0.4656 x Packing3D [52]. TSPO model structure
with the Z-score of -0.465 which was based on Bacillus cereus TSPO structure (PDB ID: 4RYO
solved at 1.6Å) was subjected to further refinement using the md_refine.mcr macro of YASARA,
while the models with lower quality Z-scores were discarded. A147T and R162H mutant struc-
tures were obtained by mutating corresponding positions in the TSPO model structure. After
the mutation, the structures were subjected to an energy minimization with the YAMBER force
field as described previously [53]. The structures of wt and mutant TSPO proteins were superim-
posed and aligned using MUSTANG program implemented in the YASARA software package
[54]. TSPO models created in this study are made available on institute homepage:
(http://www.uni-regensburg.de/medizin/psychiatrie-psychotherapie/forschung/
molekulare-neurowissenschaften/data/index.html).
Molecular dynamics simulation
Molecular dynamics (MD) simulation technique was used in order to understand the effect of
point mutations on TSPO protein structure and stability. The energy minimised structures of
the native and mutant TSPO proteins were used as starting points for the MD simulations,
which were carried out with YASARA software using the md_runmembrane.mcr macro and
the AMBER04 force field.
The TSPO simulation was set up automatically by first scanning the protein for exposed
transmembrane helices. Based on the identified secondary structure elements, the protein was
oriented normally with respect to the plane of the membrane and the XZ-plane. The equili-
brated membrane, consisting of phosphatidylethanolamine molecules was enclosed in the sim-
ulation cell of size [69x98x65] Å and the native or mutant proteins were then embedded into
the membrane. The simulation cell contained around 22 000 atoms which included the TSPO
protein together with phosphatidylethanolamine and water molecules. During the equilibra-
tion phase which lasted 250 ps, the membrane was artificially stabilized to avoid distortions
while the simulation cell adapted to the pressure exerted by the membrane. The MD was run
for 30–35 ns at constant temperature of 298K, and pressure with a time step of 2 fs and snap-
shots were saved at every 25 ps, as defined in md_runmembrane.mcr macro.
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The trajectory files generated by MD simulations were analysed using YASARA to obtain
the root-mean-square deviation (RMSD), root-mean-square-fluctuation (RMSF), and radius
of gyration (Rg) values, which were statistically analysed to determine the differences in the
RMSD, RMSF, and Rg values between native and mutant protein structures.
Study approval
The present study has obtained approval of the ethics review board of the University of
Regensburg, Germany (Reference No. 13-101-0271) and has been performed in accordance
with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amend-
ments. Participants were recruited from March 09, 2015 to September 19, 2016, from students,
staff, and employees of University of Regensburg. All the participants were healthy, free from
any medication and skin allergy. Informed consent was given by each proband participating in
the study.
Cell lines and culture conditions
Adult human dermal primary fibroblasts were derived from the skin biopsies of different
donors harbouring either wild-type genotype or, homozygous genotype for A147T, or R162H
TSPO mutations. Healthy skin (4 mm) was obtained according to standard protocols from the
Department of Dermatology, University Hospital Regensburg, Germany. Dermal tissue was
cut into 0.5-mm pieces and subsequently seeded in 6 well cell culture dishes in fibroblast
growth medium (DMEM high-glucose with 4.5 g/l L-glutamine, supplemented with 10% fetal
calf serum, 100 U/ml penicillin and 0.1 mg/ml streptomycin, Thermo Fischer Scientific,
Darmstadt, Germany). After 10–15 days, an outgrowth of single fibroblasts was observed. Cul-
tures were maintained in humidified air (5% CO2) at 37
o C, and medium was changed three
times a week. After reaching 80% confluency, cells were detached using trypsin–EDTA
(Thermo Fischer Scientific, Darmstadt, Germany) and subcultured in 75-cm2 cell culture
flasks with fibroblast growth medium.
Genotyping of rs6791 and rs6792 SNPs in TSPO
Genomic DNA was extracted from 4 ml of whole blood with QIAamp DNA blood maxi kit
(Qiagen, Hilden, Germany) according to the manufacturer’s protocol. DNA quality was
assessed utilizing optical absorbance and gel electrophoresis. Exon 4 of the TSPO gene con-
taining the polymorphisms rs6971 (Ala or Thr at position 147), and rs6972 (Arg or His at posi-
tion 162), as well as protein coding exons 2 and 3 and their respective exon/intron junctions
were PCR amplified and sequenced using Sanger method. Sequencing primers used in this
study are listed in S4 Table. Sequencing data were analysed using SnapGene software (from
GSL Biotech; available at snapgene.com).
Western blot and TSPO antibody generation
Whole cell protein samples were sonicated and boiled in RIPA buffer and total protein was
quantified using a micro-BCA colorimetric assay (Pierce, Thermo Fischer Scientific). Protein
samples were separated by SDS-polyacrylamide gel electrophoresis on 15% gels and subse-
quently transferred onto Immobilon1-P PVDF membrane (Millipore, Bedford, MA, USA).
Incubation of primary and secondary antibodies was carried out at 4˚C ON, respectively.
The peptide RDNHGWRGGRRLPE containing amino acids 156–169 of human TSPO was
used to generate affinity-purified rabbit polyclonal antibody (Davids Biotech, Regensburg,
Germany). Specificity of this antibody termed anti TSPO-MIL was tested by western blotting,
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and immunostaining (S3 Fig). Western blot and immunocytochemistry were performed using
either plain primary antibody diluted 1:5000 for western blotting and 1:500 for immunocyto-
chemistry or primary antibody incubated with 1 μg/ml of blocking peptide for 1 hour. ATP
synthase beta subunit mouse monoclonal antibody (ab14730, Abcam, Cambridge, UK) was
used in 1:1000 dilution for specific mitochondrial staining.
Cycloheximide protein degradation assay and quantitative Western blot
analysis
The turnover of proteins was determined using cycloheximide inhibition of protein de novo
synthesis. Cells were seeded into 6 well plates, and subsequently treated with 25 μg/ml cyclo-
heximide (Sigma, Taufkirchen, Germany) for the indicated time points.
Proteins were separated by SDS-PAGE and blotted onto Immobilon1-FL membrane
(LI-COR Bioscience, Bad Homburg, Germany). TSPO protein was detected using the TSPO-
MIL antibody, multiplexed with beta 1 tubulin antibody (clone E7, Developmental Studies
Hybridoma Bank, Iowa, USA) which was used as a loading control. IRDye 700 and 800 infra-
red secondary antibodies were used for simultaneous detection using the Odyssey Infrared
imaging system (LI-COR Bioscience, Bad Homburg, Germany). TSPO band densities were
quantified with Odyssey Image Studio v4.0 software as percentage of the initial TSPO protein
level (0h of CHX treatment) and normalized against beta 1 tubulin signal from the same blot.
Statistical analysis
Statistical analysis were performed with Sigma Plot 12 (Systat Software, San Jose, USA), and
Igor Professional 6.37 (Wavemetrics, Portland, USA). Data were tested for normal distribution
prior to the statistical analysis. Parametric data were tested with Student’s t-test and nonpara-
metric data with the Wilcoxon signed-rank test. Level of significance was set at p< 0.05. All
data were presented as mean ± SEM.
Supporting information
S1 Fig. ConSurf conserved regions. The ConSurf algorithm at consurf.tau.ac.il. was used to
provide conservation score for the amino acids of human TSPO. Interestingly, 11 out of 21 of
the predicted deleterious mutations occur in highly conserved regions of TSPO, depicted in
dark violet colour. Remarkably, all of them but 2 cluster in 2 conserved amino acid stretches in
TMD2 (aa 44–65) and in TMD5 (aa 133–150), which are facing each other.
(TIF)
S2 Fig. Codon usage analysis of human TSPO gene. Relative adaptiveness values for wt
TSPO codons are shown in black, whereas three sSNPs with strongest effect on codon usage
are depicted in red. The SNPs at positions 113 and 114 which are located in a rare codon usage
cluster are showing large reduction of relative adaptiveness values from 100 to 18.
(TIF)
S3 Fig. Confirmation of antibody specificity by peptide blocking. Western blot and immu-
nocytochemistry were performed using either plain primary antibody or primary antibody
incubated with 1 μg/ml of peptide which was used to generate the anti-TSPO antibody. (A)
Western blot analyses of protein extracts from HEK-293 cells and fibroblasts revealed single
bands corresponding to the molecular size of TSPO, which disappeared after incubation with
blocking peptide, thus confirming antibody specificity. Beta 1 tubulin antibody was used as
loading control. (B) Similar results were obtained using immunocytochemistry, where co-
localisation of TSPO with ATPB confirmed mitochondrial localisation of TSPO. Scale bar
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10 μm.
(TIF)
S1 Table. List of all TSPO SNPs.
(DOCX)
S2 Table. ConSurf table, conservation score.
(DOCX)
S3 Table. Codon usage analysis results.
(DOCX)
S4 Table. Primers used for sequencing.
(DOCX)
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